A Multicenter, Non-interventional, Two-cohort Study to Describe Real-world Treatment Patterns and Outcomes in Patients With Peripheral T-cell Lymphoma
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).
• Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.
• Cohort B: Patients newly diagnosed from October 2025 onward.
• Availability of basic diagnostic and treatment records .
Locations
Other Locations
China
Fudan University Shanghai Cancer Center
RECRUITING
Shanghai
Contact Information
Primary
Rong Tao, MD
hkutao@hotmail.com
008621-64175590
Backup
Chuanxu Liu, MD
liuchaunxu@shca.or.cn
008621-64175590
Time Frame
Start Date:2025-11-15
Estimated Completion Date:2035-12-31
Participants
Target number of participants:3000
Treatments
Cohort A (Retrospective)
A retrospective cohort of cases diagnosed between 2010 and 2024, assembled from medical-record data.~Target enrollment: 1,300-1,500 patients.
Cohort B (Prospective)
A prospective cohort of patients newly diagnosed between 2025 and 2030, ensuring ≥5-year follow-up for all survivors.~Target sample size: 1,000-1,500 cases, estimated from participating centers' annual diagnostic volumes over a 5-year accrual period. The cohort should be multidimensionally representative, including: (i) geographic coverage across North, East, South, Southwest, and Northeast China; (ii) hospital tiers with tertiary (Class III Grade A) institutions as the core and selective inclusion of prefecture-level hospitals; and (iii) economic diversity spanning regions with differing levels of socioeconomic development.